|
|
News Breaks
|
December 8, 2009
|
| 07:53 EDT |  | CELG |
| theflyonthewall.com: | Celgene volatility low; shares sell off after presentation | | Celgene is recently down $2.33 to $53.20 in pre-open trading. CELG presented Phase 3 MM-015 data of Revlimid in 1st line maintenance therapy (FLMT) of multiple myeloma. Goldman Sachs say's "We expect CELG to be under pressure because the MM-015 data raise concerns about the competitiveness, regulatory approval, reimbursement, and adoption of Revlimid." CELG over all option implied volatility of 35 is below its 26-week average of 39, according to Track Data, suggesting decreasing price movement. :theflyonthewall.com |
|
|
News For CELG From The Last 14 Days Check below for free stories on CELG the last two weeks.
There are 3 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
May 23, 2012
|
| 07:10 EDT |  | CELG |
| theflyonthewall.com: | FTC, Senate probing blocking of generic drug companies, Washington Post says | | The Federal Trade Commission and the U.S. Senate are investigating whether pharmaceutical companies are using a loophole to prevent generic drug makers from obtaining samples of brand name drugs, according to The Washington Post. The FDA requires generic drug makers to test a sample of brand name versions in order to get a generic drug approved, the newspaper notes. Reference Link :theflyonthewall.com |
|
|
May 10, 2012
|
| 07:38 EDT |  | CELG |
| | 04:20 EDT | | CELG |
|
|
|
|
|
Subscribe for More Information